Boryung announced on the 4th that it has signed a license agreement with Antengene, a Chinese pharmaceutical company specializing in anticancer drug development, for blood cancer drug Xpovio (generic name: selinexor).
Under the agreement, Boryung has secured exclusive rights including domestic sales, distribution, and regulatory approval for Xpovio, and began full-scale domestic supply last month.
Xpovio is a treatment for multiple myeloma and diffuse large B-cell lymphoma. It is the world's first selective nuclear export protein (XPO1) inhibitor with a novel mechanism of action.
By inhibiting nuclear export protein function, tumor suppressor proteins and growth regulatory proteins are prevented from exiting the cell nucleus, causing them to accumulate and activate within the nucleus, thereby inducing cancer cell death.
With the addition of Xpovio, Boryung has expanded its blood cancer treatment portfolio to a total of eight drugs.